BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31814710)

  • 1. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
    Zhang J; Li A; Jiang Q; Zheng F; Zhu H
    Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
    Cui Q; Hu Y; Ma D; Liu H
    Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
    Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
    Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
    J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
    Chen W; Li Z; Zheng Z; Wu X
    Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
    JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
    Yang H; Geng A; Wang Z; Wu C
    J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
    Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
    Jin M; Cai J; Wang X; Zhang T; Zhao Y
    Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
    Kato MK; Yunokawa M; Bun S; Shimoi T; Yonemori K; Miyasaka N; Kato T; Tamura K
    J Cancer Res Clin Oncol; 2020 May; 146(5):1335-1341. PubMed ID: 32144536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
    Conteduca V; Gurioli G; Rossi L; Scarpi E; Lolli C; Schepisi G; Farolfi A; De Lisi D; Gallà V; Burgio SL; Menna C; Amadori A; Losi L; Amadori D; Costi MP; De Giorgi U
    BMC Cancer; 2018 Dec; 18(1):1267. PubMed ID: 30567527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study.
    Huang Q; Chu C; Tang J; Dai Z
    J Cancer; 2020; 11(18):5353-5358. PubMed ID: 32742481
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
    Chikazawa K; Netsu S; Kuwata T; Konno R
    Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.
    Zhang M; Tian Z; Sun Y
    Medicine (Baltimore); 2017 Nov; 96(45):e8570. PubMed ID: 29137078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.